Significant Portfolio Growth
Completed two innovative transactions for Casgevy and Sebetralstat, deploying a total of $162 million with a potential deal size of up to $241 million. Expanded credit facilities from $500 million to $632 million, providing additional capital for strategic investments.
Strong Financial Performance
Recorded $38.9 million in normalized total cash receipts, a 54% increase over the same quarter in 2023. Adjusted EBITDA increased by 53% to $31.3 million compared to the same quarter in 2023, with a margin of 80%.
Royalty Receipts Growth
Royalty receipts increased 54% year-over-year, driven by Orserdu and Empaveli sales, with OMIDRIA receipts increasing 195% from the previous year.
Pipeline and Market Opportunities
Robust pipeline with over $3 billion in potential opportunities. Significant tailwinds from biotech market conditions, providing opportunities for further strategic investments.